CO6382110A2 - Compuestos para el tratamiento de la hepatitis c. - Google Patents
Compuestos para el tratamiento de la hepatitis c.Info
- Publication number
- CO6382110A2 CO6382110A2 CO11041979A CO11041979A CO6382110A2 CO 6382110 A2 CO6382110 A2 CO 6382110A2 CO 11041979 A CO11041979 A CO 11041979A CO 11041979 A CO11041979 A CO 11041979A CO 6382110 A2 CO6382110 A2 CO 6382110A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- treatment
- hcv
- hepatitis
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
La invención se refiere de forma general a los compuestos novedosos de la fórmula I, incluyendo sus sales, que presentan actividad contra el virus de la hepatitis C (HCV) y son útiles en el tratamiento de los infectados por HCV. La invención también se refiere a composiciones y procedimientos para usar estos compuestos. La invención proporciona ventajas técnicas, por ejemplo, los compuestos son novedosos y son eficaces contra la hepatitis C. Además, los compuestos proporcionan ventajas para usos farmacéuticos, por ejemplo, con respecto a uno o más de sus mecanismos de acción, unión, eficacia de inhibición, selectividad por la diana, solubilidad, perfiles de seguridad o biodisponibilidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9600508P | 2008-09-11 | 2008-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6382110A2 true CO6382110A2 (es) | 2012-02-15 |
Family
ID=41226922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11041979A CO6382110A2 (es) | 2008-09-11 | 2011-04-05 | Compuestos para el tratamiento de la hepatitis c. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8048887B2 (es) |
EP (1) | EP2326633B1 (es) |
JP (1) | JP5685191B2 (es) |
KR (1) | KR20110059875A (es) |
CN (1) | CN102209717B (es) |
AR (1) | AR073740A1 (es) |
AU (1) | AU2009291966B2 (es) |
BR (1) | BRPI0918174A2 (es) |
CA (1) | CA2736988A1 (es) |
CL (2) | CL2011000527A1 (es) |
CO (1) | CO6382110A2 (es) |
EA (1) | EA019185B1 (es) |
IL (1) | IL211509A0 (es) |
MX (1) | MX2011002410A (es) |
NZ (1) | NZ591172A (es) |
PE (1) | PE20110806A1 (es) |
TW (2) | TW201124403A (es) |
WO (1) | WO2010030592A1 (es) |
ZA (2) | ZA201101739B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
CA2741648A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
WO2010149578A2 (en) * | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel biphenyl and phenyl-pyridine amides |
CN102639496B (zh) | 2009-09-25 | 2014-10-29 | 奥瑞泽恩基因组学股份有限公司 | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
US8324212B2 (en) | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AR080433A1 (es) * | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. |
US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
JP2013522192A (ja) * | 2010-03-11 | 2013-06-13 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎の処置のための化合物 |
EP2560947B1 (en) | 2010-04-19 | 2016-10-12 | Oryzon Genomics, S.A. | Lysine specific demethylase-1 inhibitors and their use |
AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
EP2566333A4 (en) | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
US8445497B2 (en) | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AU2011284688B2 (en) | 2010-07-29 | 2015-07-16 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use |
EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012058125A1 (en) | 2010-10-26 | 2012-05-03 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
WO2012072713A2 (en) * | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
US8507683B2 (en) * | 2010-12-09 | 2013-08-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2013033900A1 (en) * | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
CN107417549A (zh) | 2011-10-20 | 2017-12-01 | 奥莱松基因组股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙基胺化合物 |
US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US9096580B2 (en) | 2012-03-27 | 2015-08-04 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis C |
WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
EP2943496B1 (en) * | 2013-01-10 | 2017-09-06 | Bristol-Myers Squibb Company | Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c |
WO2014121416A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US8962651B2 (en) | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US9738653B2 (en) | 2013-03-14 | 2017-08-22 | Bristol-Myers Squibb Company | Fused furans for the treatment of hepatitis C |
WO2014205593A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
US9556162B2 (en) | 2013-12-13 | 2017-01-31 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
US9920036B2 (en) * | 2014-03-21 | 2018-03-20 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C |
ES2688554T3 (es) * | 2014-03-21 | 2018-11-05 | Bristol-Myers Squibb Company | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis C |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
WO2016133970A1 (en) * | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofurans substituted with primary benzamide as hcv inhibitors |
US10570108B2 (en) | 2015-02-19 | 2020-02-25 | Bristol-Myers Squibb Company | Substituted benzofuran compounds for the treatment of hepatitis C |
WO2016133961A1 (en) * | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors |
US10087167B2 (en) | 2015-02-19 | 2018-10-02 | Bristol-Myers Squibb Company | Benzofurans substituted with secondary benzamide as HCV inhibitors |
JP2018509401A (ja) * | 2015-02-23 | 2018-04-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎の治療のための新規化合物 |
WO2017165233A1 (en) * | 2016-03-21 | 2017-09-28 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
IL268683B2 (en) | 2017-02-17 | 2023-04-01 | Eidos Therapeutics Inc | Processes for the preparation of ag-10, its intermediates and salts |
KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
JP2021518381A (ja) | 2018-03-23 | 2021-08-02 | エイドス セラピューティクス,インコーポレイティド | Ag10を使用するttrアミロイドーシスの治療方法 |
KR20210046708A (ko) | 2018-08-17 | 2021-04-28 | 에이도스 테라퓨틱스, 인코포레이티드 | Ag10의 제형 |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
WO2021008512A1 (zh) * | 2019-07-18 | 2021-01-21 | 石药集团中奇制药技术(石家庄)有限公司 | 作为nmt抑制剂的化合物及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US20050107400A1 (en) | 2001-03-30 | 2005-05-19 | Boyd Leslie F. | Use of pyrazolopyridines as therapeutic compounds |
EA009943B1 (ru) | 2002-11-01 | 2008-04-28 | Вирофарма Инкорпорейтед | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
TW200815384A (en) * | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
MX2009008439A (es) * | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
CN101910145A (zh) * | 2008-02-14 | 2010-12-08 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
-
2009
- 2009-09-04 US US12/554,193 patent/US8048887B2/en active Active
- 2009-09-08 CA CA2736988A patent/CA2736988A1/en not_active Abandoned
- 2009-09-08 EP EP09792299.1A patent/EP2326633B1/en not_active Not-in-force
- 2009-09-08 MX MX2011002410A patent/MX2011002410A/es active IP Right Grant
- 2009-09-08 EA EA201100390A patent/EA019185B1/ru not_active IP Right Cessation
- 2009-09-08 NZ NZ591172A patent/NZ591172A/xx not_active IP Right Cessation
- 2009-09-08 WO PCT/US2009/056166 patent/WO2010030592A1/en active Application Filing
- 2009-09-08 CN CN200980144912.3A patent/CN102209717B/zh not_active Expired - Fee Related
- 2009-09-08 AU AU2009291966A patent/AU2009291966B2/en not_active Ceased
- 2009-09-08 PE PE2011000445A patent/PE20110806A1/es active IP Right Grant
- 2009-09-08 BR BRPI0918174A patent/BRPI0918174A2/pt not_active IP Right Cessation
- 2009-09-08 KR KR1020117008085A patent/KR20110059875A/ko not_active Application Discontinuation
- 2009-09-08 JP JP2011526931A patent/JP5685191B2/ja not_active Expired - Fee Related
- 2009-09-11 AR ARP090103514A patent/AR073740A1/es not_active Application Discontinuation
- 2009-09-11 TW TW100113021A patent/TW201124403A/zh unknown
- 2009-09-11 TW TW098130829A patent/TW201014836A/zh unknown
-
2011
- 2011-03-01 ZA ZA2011/01739A patent/ZA201101739B/en unknown
- 2011-03-01 IL IL211509A patent/IL211509A0/en unknown
- 2011-03-11 CL CL2011000527A patent/CL2011000527A1/es unknown
- 2011-04-05 CO CO11041979A patent/CO6382110A2/es not_active Application Discontinuation
- 2011-05-25 CL CL2011001224A patent/CL2011001224A1/es unknown
- 2011-08-03 ZA ZA2011/05720A patent/ZA201105720B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ591172A (en) | 2012-12-21 |
JP2012502101A (ja) | 2012-01-26 |
WO2010030592A1 (en) | 2010-03-18 |
EA201100390A1 (ru) | 2011-10-31 |
CN102209717B (zh) | 2015-02-18 |
US20100093694A1 (en) | 2010-04-15 |
EA019185B1 (ru) | 2014-01-30 |
PE20110806A1 (es) | 2011-10-31 |
EP2326633B1 (en) | 2015-12-16 |
CN102209717A (zh) | 2011-10-05 |
EP2326633A1 (en) | 2011-06-01 |
TW201124403A (en) | 2011-07-16 |
AU2009291966A1 (en) | 2010-03-18 |
TW201014836A (en) | 2010-04-16 |
CA2736988A1 (en) | 2010-03-18 |
CL2011000527A1 (es) | 2011-08-12 |
BRPI0918174A2 (pt) | 2019-10-01 |
ZA201101739B (en) | 2012-08-29 |
ZA201105720B (en) | 2012-08-29 |
JP5685191B2 (ja) | 2015-03-18 |
IL211509A0 (en) | 2011-07-31 |
CL2011001224A1 (es) | 2011-09-16 |
MX2011002410A (es) | 2011-04-05 |
AU2009291966B2 (en) | 2014-08-28 |
US8048887B2 (en) | 2011-11-01 |
AR073740A1 (es) | 2010-12-01 |
KR20110059875A (ko) | 2011-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6382110A2 (es) | Compuestos para el tratamiento de la hepatitis c. | |
EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
BR112015004113A2 (pt) | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b | |
CR20150454A (es) | Compuestos amida para el tratamiento de vih | |
SV2011003903A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes | |
BR112012014858A2 (pt) | agente antiplaqueta | |
CU20110191A7 (es) | Compuestos orgánicos y sus usos | |
BR112013028487A2 (pt) | inibidores do vírus da hepatite c | |
CO6440581A2 (es) | Inhibidores del virus de la hepatitis c | |
NO341663B1 (no) | Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer | |
EA201001275A1 (ru) | Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
EA201001273A1 (ru) | Ингибиторы вируса гепатита с | |
ECSP099601A (es) | Inhibidores de proteasa de serina | |
DOP2010000084A (es) | Derivado de uracilo o timina para el tratamiento de hepatitis c | |
BR112013032049A2 (pt) | inibidores do vírus da hepatite c | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
EA201370078A1 (ru) | Ингибиторы вируса гепатита с | |
CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
BR112014010401A8 (pt) | Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |